Models of Pancreatic Cancer: Understanding Disease Progression

  • Laleh G. Melstrom
  • Paul J. Grippo
Part of the M. D. Anderson Solid Tumor Oncology Series book series (MDA)

This book focuses on pancreatic cancer, which is a highly aggressive cancer that kills more than half of all of its victims within 6 months after the initial diagnosis. This dismal prognosis is due to late diagnosis, an incomplete knowledge of the pathways that generate invasive and metastatic disease, and a lack of efficacious therapies. Since patients present at such a late stage, it is extremely difficult to improve our understanding of markers of early detection, causative genetic events, and effective targets for treatment. Thus, investigations must initially concentrate on modeling systems that recapitulate the human disease at both the cellular and tissue levels. It is these systems that shed light onto the etiology of pancreatic cancer and provide the means of experimentation aimed at improving overall patient survival. Hence, the theme of this chapter is on models of pancreatic cancer and how these models help address important issues in this field of research.

One of the most pressing needs in regard to pancreatic cancer research is understanding the transitional step between PanIN development and invasive disease. Herein lies the key between early lesions and lethal cancer-identifying the causative genetic events that can serve as targets for earlier detection, chemoprevention, and therapy. Unfortunately, these types of evaluations in humans are restricted by presentation of this disease at a very late stage (metastasis). To begin unraveling the genetic alterations and epigenetic contributions that promote progression to cancer, a variety of modeling systems are needed. These models can be used in various applications, but for the sake of this chapter, attention is focused on the in vitro, ex vivo, and in vivo models of pancreatic precancer and cancer that highlight various aspects of the invasive phenotype in humans. A brief discussion of many of these models will help guide investigations focused on understanding the progression from precancer to adenocarcinoma and how particular models can suit a specific analysis.

Many of these models help address critical issues regarding the invasive nature of pancreatic cancer while providing the means with which to assess early detection schemes and evaluate novel chemoprevention and anticancer compounds. This chapter is divided into four broad sections: ( 1 ) pancreatic cancer cells in culture, ( 2 ) subcutaneous/orthotopic xenografts, ( 3 ) chemically induced rodents, and ( 4 ) genetically engineered mice.


Pancreatic Cancer Acinar Cell Pancreatic Cancer Cell Pancreatic Adenocarcinoma Pancreatic Ductal Adenocarcinoma 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Moore PS, Sipos B, Orlandini S, 2001, Genetic profile of 22 pancreatic carcinoma cell lines Analysis f K-ras, p53, p16 and DPC4/Smad4. Virchows Arch 439:798–802.PubMedGoogle Scholar
  2. 2.
    Sipos B, Moser S, Kalthoff H, 2003, A comprehensive characterization of pancreatic ductal carcinoma cell lines: towards establishment of an in vitro research platform. Virchows Arch 442:444–452.PubMedGoogle Scholar
  3. 3.
    Almoguera C, Shibata D, Forrester K, 1988, Most human carcinomas of the exocrine pancreas contain mutant c-Kras genes. Cell 53:549–54.PubMedGoogle Scholar
  4. 4.
    Caldas C, Hahn SA, Costa L, da 1994, Frequent somatic mutations and homozygous deletions of the p16 (MTS1) gene in pancreatic adenocarcinoma. Nat Genet 8:27–32.PubMedGoogle Scholar
  5. 5.
    Kalthoff H, Schmiegel W, Roeder C, 1993, p53 and K-RAS alteration in pancreatic epithelial cell lesions. Oncogene 8:289–298.PubMedGoogle Scholar
  6. 6.
    Lemoine NR, Jain S, Hughes CM, 1992, Ki-ras oncogene activation in preinvasive pancreatic cancer. Gastroenterology 102:230–236.PubMedGoogle Scholar
  7. 7.
    Redston MS, Caldas C, Seymour AB, 1994, p53 mutations in pancreatic carcinoma and evidence of common involvement of homocopolymer tracts in DNA microdeletions. Cancer Res 54:3025–3033.PubMedGoogle Scholar
  8. 8.
    Ruggeri B, Zhang SY, Caamano J, 1992, Human pancreatic carcinomas and cell lines reveal frequent and multiple alterations in the p53 and Rb-1 tumor-suppressor genes. Oncogene 7:1503–1511.PubMedGoogle Scholar
  9. 9.
    Scarpa A, Capelli P, Mukai K, 1993, Pancreatic adenocarcinoma frequently show p53 gene mutations. Am J Pathol 142:1534–1543.PubMedGoogle Scholar
  10. 10.
    Scarpa A, Capelli P, Villanueva A, 1994, ;Pancreatic cancer in Europe: Ki-ras gene mutation pattern shows geographical differences. I nt J Cancer 57:167–171.Google Scholar
  11. 11.
    Smit V, Boot AM, Smits AM, 1988, K-ras codon 12 mutations occur very frequently in pancreatic adenocarcinoma. Nucleic Acids Res 16:7773–7782.PubMedGoogle Scholar
  12. 12.
    Furukawa T, Sunamura M, Horii A, 2006, Molecular mechanisms of pancreatic carcinogene-sis. Cancer Sci 97:1–7.PubMedGoogle Scholar
  13. 13.
    Serrano M, Hannon GJ, Beach D, 1993, A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature 366:704–707.PubMedGoogle Scholar
  14. 14.
    Nakamura Y, 2004, I solation of p53-target genes and their functional analysis. Cancer Sci 95:7–11.PubMedGoogle Scholar
  15. 15.
    Hahn SA, Schutte M, Hogque AT, 1996, DPC4, a candidate tumor suppressor gene at human chromosome 18q21.1. Science 271:350–353.PubMedGoogle Scholar
  16. 16.
    Miyazono K, Suzuki H, Imamura T, 2003, Regulation of TGF-beta signalling and its roles in progression of tumors. Cancer Sci 94:230–234.PubMedGoogle Scholar
  17. 17.
    Luttges J, Schemm S, Vogel I, 2000, The grade of pancreatic ductal carcinoma is an independ-ent prognostic factor and is superior to the immunohistochemical assessment of proliferation. J Pathol 191:154–161.PubMedGoogle Scholar
  18. 18.
    Herzig KH, Altmannsberger M, Folsche UR, 1994, Intermediate filaments in rat pancreatic acinar tumors, human ductal carcinomas, and other gastrointestinal malignancies. Gastroenterology 106:1326–1332.PubMedGoogle Scholar
  19. 19.
    Heyderman E, Larkin SE, O’Donnell PJ, 1990, Epithelial markers in pancreatic adenocarci-noma: immunoperoxidase localisation of DD9, CEA, EMA and CAM 5.2. J Clin Pathol 43:448–452.PubMedGoogle Scholar
  20. 20.
    Rafiee P, Ho SB, Bresalier RS, 1992, Characterization of the cytokeratins of human colonic, pancreatic, and gastric adenocarcinoma cell lines. Pancreas 7:123–131.PubMedGoogle Scholar
  21. 21.
    Santini D, Ceccarelli C, Martinelli GN, 1994, Expression of intermediate filaments in normal and neoplastic exocrine pancreas. Zentralbl Pathol 140:247–258.PubMedGoogle Scholar
  22. 22.
    Hoorens A, Prenzel K, Lemoine NR, 1998, Undifferentiated carcinoma of the pancreas: analysis of intermediate filament profile and Ki-ras mutations provides evidence of a ductal origin. J Pathol 185:53–60.PubMedGoogle Scholar
  23. 23.
    Cubilla AL, Fitzgerald PJ, 1976, Morphological lesions associated with human primary invasive nonendocrine pancreas cancer. Cancer Res 36:2690–2698.PubMedGoogle Scholar
  24. 24.
    Hruban RH, Takaori K, Klimstra DS, 2004, An illustrated consensus on the classification of panreatic intraepithelial neoplasia and intraductal papillary mucinous neoplasms. Am J Surg Pathol 28:977–987.PubMedGoogle Scholar
  25. 25.
    Eckel F, Schneider G, Schmid R, 2006, Pancreatic cancer: a review of recent advances. Epert Opin Ivestig Drugs 15(11):1395–1410.Google Scholar
  26. 26.
    Lawson T, Ouellette M, Kolar C, 2005, Culture and immortalization of pancreatic ductal epi-thelial cells. methods in molecular medicine pancreatic cancer. Methods Protocols 103:113–122.Google Scholar
  27. 27.
    Jones RT, Hudson EA, Resau JH. 1981, A review of in vitro and in vivo culture techniques for the study of pancreatic carcinogenesis. Cancer 47:1490–1406.PubMedGoogle Scholar
  28. 28.
    Gmyr V, Kerr-Conte J, Vanderwalle B, 2001, Human pancreatic ductal cells: Large scale iso-lation and expansion. Cell Transplant 10:109–121.PubMedGoogle Scholar
  29. 29.
    Lisle RC, de Logsdon CD. 1990, Pancreatic acinar cells in culture: expression of acinar and ductal antigens in a growth-related manner. Eur J Cell Biol 51:64–75.PubMedGoogle Scholar
  30. 30.
    Ouellette MM, Lee K. 2001, Telomerase: diagnostics, cancer therapeutics and tissue engineer-ing. Dru Discov Today 6:1231–1237.Google Scholar
  31. 31.
    Bodnar AG, Ouellette M, Frolkis M, 1998, Extension of life-span by introduction of telomer-ase into normal human cells. Science 279:349–352.PubMedGoogle Scholar
  32. 32.
    Morales CP, Holt SE, Ouellet MM, 1999, Absence of cancer-associated changes in human fibroblasts immortalized with telomerase. Nat Genet 21:115–118.PubMedGoogle Scholar
  33. 33.
    Jiang XR, Jimenez G, Change E, 1999, Telomerase expression in human somatic cells does not induce changes associated with a transformed phenotype. Nat Genet 21:111–114.PubMedGoogle Scholar
  34. 34.
    Jesnowski R, Muller P, Schareck W, 1999, I mmortalized pancreatic duct cells in vitro and in vivo. Ann N Y Acad Sci 880:50–65.PubMedGoogle Scholar
  35. 35.
    Furukawa T, Duguid WP, Rosenberg L, 1996, Long-term culture and immortalization of epi-thelial cells from normal adult human pancreatic ducts transfected by the E6E7 gene of human papilloma virus 16. Am J Pathol 148:1763–1770.PubMedGoogle Scholar
  36. 36.
    Jesnowski R, Liebe S, Lohr M. 1998, Increasing the transfection efficacy and subsequent long-term culture of resting human pancreatic duct epithelial cells. Pancreas 17:262–265.PubMedGoogle Scholar
  37. 37.
    Ulrich AB, Schmied BM, Standop J, 2002, Pancreatic cell lines: a review. Pancreas 24:111–120.PubMedGoogle Scholar
  38. 38.
    Grippo PJ, Sandgren EP, 2005, Modeling pancreatic cancer in animals to address specific hypothesis. Methods Mol, Med 103:217–243.Google Scholar
  39. 39.
    Fidler IJ, 1986, Rationale and methods for the use of nude mice to study the biology and therapy of human cancer metastasis. Cancer Metastasis Rev 5 (1):29–49.PubMedGoogle Scholar
  40. 40.
    Capella G, Farre L, Villanueva A, 1999, Orthotopic models of human pancreatic cancer. Ann N Y Acad Sci 880:103–109.PubMedGoogle Scholar
  41. 41.
    Fogh J, Orfeo T, Tiso J, 1980, Twenty-three new human tumor lines established in nude mice. Exp Cell Biol 880:229–239.Google Scholar
  42. 42.
    Alisauskus R, Wong GY, Gold DV, 1995, Initial studies of monoclonal antibody PAM4 targeting to xenografted orthotopic pancreatic cancer. Cancer Res 55: 5743s – 48s.PubMedGoogle Scholar
  43. 43.
    Luokopoulos P, Kanetaka K, Takamura M, 2004, Orthotopic transplantation models of pan-creatic adenocarcinoma derived from cell lines and primary tumors and displaying varying metastatic activity. Pancreas 29:193–203.Google Scholar
  44. 44.
    Ellenrieder V, Adler G, Gress TM, 1999, I nvasion and metastasis in pancreatic cancer. Ann Oncol 10(Suppl 4):46–50.PubMedGoogle Scholar
  45. 45.
    Keleg S, Buchler P, Ludwig R, 2003, I nvasion and metastasis in pancreatic cancer. Mol Cancer 2:14.PubMedGoogle Scholar
  46. 46.
    L AC. Modulation of response to tumor therapies by the extracellular matrix. Future Oncol 2006, 2(3):417–429.Google Scholar
  47. 47.
    Petrulio CA, Kim-Schulze S, Kaufman HL. 2006, The tumour microenvironment and implications for cancer immunotherapy. Expert Opin Biol Ther 6 (7):671–684.PubMedGoogle Scholar
  48. 48.
    Tan MH, Chu TM. 1985, Characterization of the tumorigenic and metastatic properties of a human pancreatic tumor cell line (AsPC-1) implanted orthotopically into nude mice. Tumour Biol 6(1):89–98.PubMedGoogle Scholar
  49. 49.
    Marincola FM, Drucker BJ, Siao DY, 1989, The nude mouse as a model or the study of human pancreatic cancer. J Surg Res 47(6):520–529.PubMedGoogle Scholar
  50. 50.
    Mohammad RM, Al-Katib A, Pettit GR, 1998, An orthotopic model of human pancreatic cancer in severe combined immunodeficient mice: potential application for preclinical studies. Clin Cancer Res 4(4):887–894.PubMedGoogle Scholar
  51. 51.
    Alves F, Contag S, Missbach M, 2001, An orthotopic model of ductal adenocarcinoma of the pancreas in severe combined immunodeficient mice representing all steps of the metastatic cascade. Pancreas 23(3):227–235.PubMedGoogle Scholar
  52. 52.
    Fu X, Guadagni F, Hoffman RM. 1992, A metastatic nude-mouse model of human pancreatic cancer constructed orthotopically with histologically intact patient specimens. Proc Natl Acad Sci USA 89:5645–5649.PubMedGoogle Scholar
  53. 53.
    Reyes G, Villanueva A, Garcia C, 1996, Orthotopic xenografts of human pancreatic carcino-mas acquire genetic aberrations during dissemination in nude mice. Cancer Res 56 (24):5713–5719.PubMedGoogle Scholar
  54. 54.
    Vezeridis MP, Doremus CM, Tibbetts LM, 1989, Invasion and metastasis following orthotopic transplantation of human pancreatic cancer in the nude mouse. J Surg Oncol 40(4):261–265.PubMedGoogle Scholar
  55. 55.
    Hotz HG, Howard AR, Hotz B, 2003, An orthotopic nude mouse model for evaluating patho-physiology and therapy of pancreatic cancer. Pancreas 26(4):89e–98e.Google Scholar
  56. 56.
    Samnick S, Romeike BF, Kubuschok B, 2004, p-[123I]iodo-L-phenylalanine for detection of pancreatic cancer: basic investigations of the uptake characteristics in primary human pancre-atic tumour cells and evaluation in in vivo models of human pancreatic adenocarcinoma. Eur J Nucl Med Mol Imaging 31(4):532–541.PubMedGoogle Scholar
  57. 57.
    Bouvet M, Yang M, Nardin S, 2000, Chronologically-specific metastatic targeting f human pancreatic tumors in orthotopic models. Clin Exp Metastasis 18(3):213–218.PubMedGoogle Scholar
  58. 58.
    Bouvet M, Spernyak J, Katz MH, 2005, High correlation of whole-body red fluorescent pro-tein imaging and magnetic resonance imaging on an orthotopic model of pancreatic cancer. Cancer Res 65(21):9829–9833.PubMedGoogle Scholar
  59. 59.
    Bouvet M, Wang J, Nardin SR, 2002, Real-time optical imaging of primary tumor growth and multiple metastatic events in a pancreatic cancer orthoptic model. Cancer Res 62:1534–1540.PubMedGoogle Scholar
  60. 60.
    Gingell R, Wallcave L, Nagel D, 1976, Metabolism of the pancreatic carcinogens N-nitroso-bis(2-oxopropyl)amine and N-nitroso-bis(2-hydroxypropyl)amine in the Syrian hamster. J Natl Cancer Inst 57(5):1175–1178.PubMedGoogle Scholar
  61. 61.
    Gingell R, Brunk G, Nagel D, 1979, Metabolism of three radiolabeled pancreatic carcinogenic nitrosamines in hamsters and rats. Cancer Res 39(11):4579–4583.PubMedGoogle Scholar
  62. 62.
    Pour P, Gingell R, Langenbach R, 1980, Carcinogenicity of N-nitrosomethyl(2-oxopropyl)amine in Syrian hamsters. Cancer Res 40(10):3585–3590.PubMedGoogle Scholar
  63. 63.
    Pour P, Mohr U, Cardesa A, 1975, Pancreatic neoplasms in an animal model: morphological, biological, and comparative studies. Cancer 36(2):379–389.PubMedGoogle Scholar
  64. 64.
    Pour P, Althoff J. 1977, The effect of N-nitrosobis(2-oxopropyl)amine after oral administration to hamsters. Cancer Lett 2(6):323–326.PubMedGoogle Scholar
  65. 65.
    Gingell R, Pour P. 1978, Metabolism of the pancreatic carcinogen N-nitroso-bis(2-oxopropyl)amine after oral and intraperitoneal administration to Syrian golden hamsters. J Natl Cancer Inst 60(4):911–913.PubMedGoogle Scholar
  66. 66.
    Roebuck BD, Baumgartner KJ, Thron CD, 1984, Characterization of two populations of pancreatic atypical acinar cell foci induced by azaserine in the rat. Lab Invest 50(2):141–146.PubMedGoogle Scholar
  67. 67.
    Longnecker DS. 1984, Lesions induced in rodent pancreas by azaserine and other pancreatic carcinogens. Environ Health Perspect 56:245–251.PubMedGoogle Scholar
  68. 68.
    Longnecker DS, Curphey TJ. 1975, Adenocarcinoma of the pancreas in azaserine-treated rats. Cancer Res 35(8):2249–2258.PubMedGoogle Scholar
  69. 69.
    Konishi Y, Denda A, Maruyama H, 1980, Pancreatic tumors induced by a single intraperito-neal injection of azaserine in partial pancreatectomized rats. Cancer Lett 9(1):43–46.PubMedGoogle Scholar
  70. 70.
    Longnecker DS, Roebuck BD, Yager JD, Jr. 1981, Pancreatic carcinoma in azaserine-treated rats: induction, classification and dietary modulation of incidence. Cancer 47(6 Suppl):1562–1572.PubMedGoogle Scholar
  71. 71.
    Roebuck BD, Longnecker DS. 1977, Species and rat strain variation in pancreatic nodule induction by azaserine. J Natl Cancer Inst 59(4):1273–1277.PubMedGoogle Scholar
  72. 72.
    Dissin J, Mills LR, Mains DL, 1975, Experimental induction of pancreatic adenocarcinoma in rats. J Natl Cancer Inst 55(4):857–864.PubMedGoogle Scholar
  73. 73.
    Hilmy AM, Kandeel KM, Selim NM. 1984, Pancreatic amylase as a tumour marker for pan-creatic cancer. Arch Geschwulstforsch 54(6):475–482.PubMedGoogle Scholar
  74. 74.
    Bockman DE, Guo J, Buchler P, 2003, Origin and development of the precursor lesions in experimental pancreatic cancer in rats. Lab Invest 83(6):853–859.PubMedGoogle Scholar
  75. 75.
    Rivera JA, Graeme-Cook F, Werner J, 1997, A rat model of pancreatic ductal adenocarci-noma: targeting chemical carcinogens. Surgery 122(1):82–90.PubMedGoogle Scholar
  76. 76.
    Reddy JK, Rao MS. 1975, Pancreatic adenocarcinoma in inbred guinea pigs induced by n-methyl-N-nitrosourea. Cancer Res 35(8):2269–2277.PubMedGoogle Scholar
  77. 77.
    Reddy JK, Svoboda DJ, Rao MS. 1974, Susceptibility of an ibred strain of guinea pigs to the induction of pancreatic adenocarcinoma by N-methyl-N-nitrosourea. J Natl Cancer Inst 52 (3):991–993.PubMedGoogle Scholar
  78. 78.
    Rao MS, Reddy JK. 1977, Pathology of tumors developed in guinea pigs given intraperitoneal injections of N-methyl-N-nitrosourea. Neoplasma 24(1):57–62.PubMedGoogle Scholar
  79. 79.
    Rao MS, Reddy JK. 1980, Histogenesis of pseudo-ductular changes induced in the pancreas of guinea pigs treated with N-methyl-N-nitrosourea. Carcinogenesis 1(12):1027–1037.PubMedGoogle Scholar
  80. 80.
    Longnecker D. 1990, Experimental pancreatic cancer: role of species, sex and diet. Bull Cancer 77(1):27–37.PubMedGoogle Scholar
  81. 81.
    Scarpelli DG, Rao MS, Reddy JK. 1984, Studies of pancreatic carcinogenesis in different animal models. Environ Health Perspect 56:217–227.Google Scholar
  82. 82.
    Zimmerman JA, Trombetta LD, Carter TH, 1982, Pancreatic carcinoma induced by N-methyl-NÎÎ-nitrosourea in aged mice. Gerontology 28(2):114–120.PubMedGoogle Scholar
  83. 83.
    Fujii K, Hayakawa T, Kikuchi M. 1994, Tumor induction in mice administered neonatally with bis(2-oxopropyl)nitrosamine. Tohoku J Exp Med 174(4):361–368.PubMedGoogle Scholar
  84. 84.
    Osvaldt AB, Wendt LR, Bersch VP, 2006, Pancreatic intraepithelial neoplasia and ductal ade-nocarcinoma induced by DMBA in mice. Surgery 140(5):803–809.PubMedGoogle Scholar
  85. 85.
    Haas MJ, Dragan YP, Hikita H, 1999, Transgene expression and repression in transgenic rats bearing the phosphoenolpyruvate carboxykinase-simian virus 40 T antigen or the phosphoenolpyruvate carboxykinase-transforming growth factor-alpha constructs. Am J Pathol 155 (1):183–192.PubMedGoogle Scholar
  86. 86.
    Alhonen L, Parkkinen JJ, Keinanen T, 2000, Activation of polyamine catabolism in trans-genic rats induces acute pancreatitis. Proc Natl Acad Sci U S A 97(15):8290–8295.PubMedGoogle Scholar
  87. 87.
    Ornitz DM, Hammer RE, Messing A, 1987, Pancreatic neoplasia induced by SV40 T-antigen expression in acinar cells of transgenic mice. Science 238(4824):188–193.PubMedGoogle Scholar
  88. 88.
    Quaife CJ, Pinkert CA, Ornitz DM, 1987, Pancreatic neoplasia induced by ras expression in acinar cells of transgenic mice. Cell 48(6):1023–1034.PubMedGoogle Scholar
  89. 89.
    Sandgren EP, Luetteke NC, Palmiter RD, 1990, Overexpression of TGF alpha in transgenic mice: induction of epithelial hyperplasia, pancreatic metaplasia, and carcinoma of the breast. Cell 61(6):1121–1135.PubMedGoogle Scholar
  90. 90.
    Sandgren EP, Luetteke NC, Qiu TH, 1993, Transforming growth factor alpha dramatically enhances oncogene-induced carcinogenesis in transgenic mouse pancreas and liver. Mol Cell Biol 13(1):320–330.PubMedGoogle Scholar
  91. 91.
    Sandgren EP, Quaife CJ, Paulovich AG, 1991, Pancreatic tumor pathogenesis reflects the causative genetic lesion. Proc Natl Acad Sci U S A 88(1):93–97.PubMedGoogle Scholar
  92. 92.
    Wagner M, Luhrs H, Kloppel G, 1998, Malignant transformation of duct-like cells originating from acini in transforming growth factor transgenic mice. Gastroenterology 115(5):1254–1262.PubMedGoogle Scholar
  93. 93.
    Greten FR, Wagner M, Weber CK, 2001, TGF alpha transgenic mice. A model of pancreatic cancer development. Pancreatology 1(4):363–368.PubMedGoogle Scholar
  94. 94.
    Schreiner B, Baur DM, Fingerle AA, 2003, Pattern of secondary genomic changes in pancreatic tumors of Tgf alpha/Trp53+/- transgenic mice. Genes Chromosomes Cancer 38(3):240–248.PubMedGoogle Scholar
  95. 95.
    Song SY, Gannon M, Washington MK, 1999, Expansion of Pdx1-expressing pancreatic epithelium and islet neogenesis in transgenic mice overexpressing transforming growth factor alpha. Gastroenterology 117(6):1416–1426.PubMedGoogle Scholar
  96. 96.
    Greten FR, Weber CK, Greten TF, 2002, Stat3 and NF-kappaB activation prevents apoptosis in pancreatic carcinogenesis. Gastroenterology 123(6):2052–2063.PubMedGoogle Scholar
  97. 97.
    Miyamoto Y, Maitra A, Ghosh B, 2003, Notch mediates TGF alpha-induced changes in epi-thelial differentiation during pancreatic tumorigenesis. Cancer Cell 3(6):565–576.PubMedGoogle Scholar
  98. 98.
    Garbe AI, Vermeer B, Gamrekelashvili J, 2006, Genetically induced pancreatic adenocarci-noma is highly immunogenic and causes spontaneous tumor-specific immune responses. Cancer Res 66(1):508–516.PubMedGoogle Scholar
  99. 99.
    Liao DJ, Wang Y, Wu J, 2006, Characterization of pancreatic lesions from MT-tgfalpha, Ela-myc and MT-tgfalpha/Ela-myc single and double transgenic mice. J Carcinog 5:19.PubMedGoogle Scholar
  100. 100.
    Brembeck FH, Schreiber FS, Deramaudt TB, 2003, The mutant K-ras oncogene causes pancreatic periductal lymphocytic infiltration and gastric mucous neck cell hyperplasia in transgenic mice. Cancer Res 63(9):2005–2009.PubMedGoogle Scholar
  101. 101.
    Thayer SP, di Magliano MP, Heiser PW, 2003, Hedgehog is an early and late mediator of pancreatic cancer tumorigenesis. Nature 425(6960):851–856.PubMedGoogle Scholar
  102. 102.
    Hingorani SR, Petricoin EF, Maitra A, 2003, Preinvasive and invasive ductal pancreatic can-cer and its early detection in the mouse. Cancer Cell 4(6):437–450.PubMedGoogle Scholar
  103. 103.
    Aguirre AJ, Bardeesy N, Sinha M, 2003, Activated Kras and Ink4a/Arf deficiency cooper-ate to produce metastatic pancreatic ductal adenocarcinoma. Genes Dev 17 (24):3112–3126.PubMedGoogle Scholar
  104. 104.
    Hingorani SR, Wang L, Multani AS, 2005, Trp53R172H and KrasG12D cooperate to pro-mote chromosomal instability and widely metastatic pancreatic ductal adenocarcinoma in mice. Cancer Cell 7(5):469–483.PubMedGoogle Scholar
  105. 105.
    Stanger BZ, Stiles B, Lauwers GY, 2005, Pten constrains centroacinar cell expansion and malignant transformation in the pancreas. Cancer Cell 8(3):185–195.PubMedGoogle Scholar
  106. 106.
    Muller-Decker K, Furstenberger G, Annan N, 2006, Preinvasive duct-derived neoplasms in pancreas of keratin5-promoter cyclooxygenase-2 transgenic mice. Gastroenterology 130(7):2165–2178.PubMedGoogle Scholar
  107. 107.
    Bardeesy N, Morgan J, Sinha M, 2002, Obligate roles for p16(Ink4a) and p19(Arf)-p53 in the suppression of murine pancreatic neoplasia. Mol Cell Biol 22(2):635–643.PubMedGoogle Scholar
  108. 108.
    Grippo PJ, Nowlin PS, Demeure MJ, 2003, Preinvasive pancreatic neoplasia of ductal phenotype induced by acinar cell targeting of mutant Kras in transgenic mice. Cancer Res 63 (9):2016–2019.PubMedGoogle Scholar
  109. 109.
    Tuveson DA, Zhu L, Gopinathan A, 2006, Mist1-KrasG12D knock-in mice develop mixed differentiation metastatic exocrine pancreatic carcinoma and hepatocellular carcinoma. Cancer Res 66(1):242–247.PubMedGoogle Scholar

Copyright information

© Springer Science + Business Media, LLC 2008

Authors and Affiliations

  • Laleh G. Melstrom
    • 1
  • Paul J. Grippo
    • 2
  1. 1.Feinberg School of MedicineNorthwestern UniversityChicagoUSA
  2. 2.Robert H. Lurie Comprehensive Cancer Center, Feinberg School of MedicineNorthwestern UniversityChicagoUSA

Personalised recommendations